Skip to main navigation Skip to search Skip to main content

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

  • Lykke M. Ørnbjerg
  • , Kathrine Rugbjerg
  • , Stylianos Georgiadis
  • , Simon H. Rasmussen
  • , Lennart Jacobsson
  • , Anne G. Loft
  • , Florenzo Iannone
  • , Karen M. Fagerli
  • , Jiri Vencovsky
  • , Maria J. Santos
  • , Burkhard Möller
  • , Manuel Pombo-Suarez
  • , Ziga Rotar
  • , Bjorn Gudbjornsson
  • , Ayse Cefle
  • , Kari Eklund
  • , Catalin Codreanu
  • , Gareth Jones
  • , Marleen van der Sande
  • , Johan K. Wallman
  • Marco Sebastiani, Brigitte Michelsen, Jakub Závada, Michael J. Nissen, Carlos Sanchez-Piedra, Matija Tomšič, Thorvardur J. Love, Heikki Relas, Corina Mogosan, Merete L. Hetland, Mikkel Østergaard
  • Copenhagen University Hospital
  • University of Gothenburg
  • Sahlgrenska Academy
  • Aarhus University Hospital
  • University of Bari Aldo Moro
  • Diakonhjemmet Hospital
  • Charles University in Prague
  • Hospital Garcia de Orta
  • Bern University Hospital
  • Complejo Hospitalario Universitario de Santiago
  • University Medical Centre Ljubljana
  • University of Ljubljana
  • National University Hospital of Iceland
  • Kocaeli University
  • Helsinki University Central Hospital
  • Carol Davila University of Medicine and Pharmacy
  • University of Amsterdam
  • University of Modena and Reggio Emilia
  • Sørlandet Hospital
  • Geneva University Hospital
  • Carlos III Health Institute
  • University of Iceland
  • University of Copenhagen
  • Skåne University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

Objective. To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods. Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results. For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion. In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex, and age at onset of disease were observed, emphasizing the potential influence of factors other than disease activity on PROs.

Original languageEnglish
Pages (from-to)378-389
Number of pages12
JournalJournal of Rheumatology
Volume51
Issue number4
DOIs
Publication statusPublished - 2024 Apr 1

Subject classification (UKÄ)

  • Clinical Medicine

Free keywords

  • epidemiology
  • fatigue
  • pain
  • psoriatic arthritis
  • tumor necrosis factor inhibitors

Fingerprint

Dive into the research topics of 'Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care'. Together they form a unique fingerprint.

Cite this